147 related articles for article (PubMed ID: 26072465)
1. Strategy for linker selection to enhance refolding and bioactivity of VAS-TRAIL fusion protein based on inclusion body conformation and activity.
Fan J; Huang L; Sun J; Qiu Y; Zhou J; Shen Y
J Biotechnol; 2015 Sep; 209():16-22. PubMed ID: 26072465
[TBL] [Abstract][Full Text] [Related]
2. Efficient refolding of the bifunctional therapeutic fusion protein VAS-TRAIL by a triple agent solution.
Fan J; Wang Z; Huang L; Shen Y
Protein Expr Purif; 2016 Sep; 125():68-73. PubMed ID: 26358405
[TBL] [Abstract][Full Text] [Related]
3. Engineering and refolding of a novel trimeric fusion protein TRAIL-collagen XVIII NC1.
Pan LQ; Xie ZM; Tang XJ; Wu M; Wang FR; Naranmandura H; Chen SQ
Appl Microbiol Biotechnol; 2013 Aug; 97(16):7253-64. PubMed ID: 23208613
[TBL] [Abstract][Full Text] [Related]
4. Overexpression and refolding of thioredoxin/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase.
Gasparian ME; Ostapchenko VG; Yagolovich AV; Tsygannik IN; Chernyak BV; Dolgikh DA; Kirpichnikov MP
Biotechnol Lett; 2007 Oct; 29(10):1567-73. PubMed ID: 17609857
[TBL] [Abstract][Full Text] [Related]
5. A simplified method for the efficient purification and refolding of recombinant human TRAIL.
Zhang Z; Hahn SB; Cao TM; King MR
Biotechnol Prog; 2020 Sep; 36(5):e3007. PubMed ID: 32329219
[TBL] [Abstract][Full Text] [Related]
6. Expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Lin Z; Lei H; Cao P
Protein Expr Purif; 2007 Feb; 51(2):276-82. PubMed ID: 17079165
[TBL] [Abstract][Full Text] [Related]
7. An improved strategy for high-level production of human vasostatin120-180.
Sun QM; Chen LL; Cao L; Fang L; Chen C; Hua ZC
Biotechnol Prog; 2005; 21(4):1048-52. PubMed ID: 16080682
[TBL] [Abstract][Full Text] [Related]
8. Optimization Studies on Prokaryotic Cell Expression of the Human Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL).
Hao L; Zhang ZG; Shi ZD; Pang K; Zhang JJ; Dong Y; Han CH
Cell Biochem Biophys; 2015 Nov; 73(2):275-279. PubMed ID: 25737132
[TBL] [Abstract][Full Text] [Related]
9. Construction and expression of sTRAIL-melittin combining enhanced anticancer activity with antibacterial activity in Escherichia coli.
Liu H; Han Y; Fu H; Liu M; Wu J; Chen X; Zhang S; Chen Y
Appl Microbiol Biotechnol; 2013 Apr; 97(7):2877-84. PubMed ID: 23149754
[TBL] [Abstract][Full Text] [Related]
10. TRAIL-CM4 fusion protein shows in vitro antibacterial activity and a stronger antitumor activity than solo TRAIL protein.
Sang M; Zhang J; Li B; Chen Y
Protein Expr Purif; 2016 Jun; 122():82-9. PubMed ID: 26926590
[TBL] [Abstract][Full Text] [Related]
11. SAC-TRAIL, a novel anticancer fusion protein: expression, purification, and functional characterization.
Zhang J; Dong W; Ren Y; Wei D
Appl Microbiol Biotechnol; 2022 Feb; 106(4):1511-1520. PubMed ID: 35133472
[TBL] [Abstract][Full Text] [Related]
12. Refolding and structural characteristic of TRAIL/Apo2L inclusion bodies from different specific growth rates of recombinant Escherichia coli.
Kang H; Sun AY; Shen YL; Wei DZ
Biotechnol Prog; 2007; 23(1):286-92. PubMed ID: 17269700
[TBL] [Abstract][Full Text] [Related]
13. Accurate quantitation for in vitro refolding of single domain antibody fragments expressed as inclusion bodies by referring the concomitant expression of a soluble form in the periplasms of Escherichia coli.
Noguchi T; Nishida Y; Takizawa K; Cui Y; Tsutsumi K; Hamada T; Nishi Y
J Immunol Methods; 2017 Mar; 442():1-11. PubMed ID: 27939301
[TBL] [Abstract][Full Text] [Related]
14. GroEL/ES mediated the in vivo recovery of TRAIL inclusion bodies in Escherichia coli.
Wang Z; Zhang M; Lv X; Fan J; Zhang J; Sun J; Shen Y
Sci Rep; 2018 Oct; 8(1):15766. PubMed ID: 30361617
[TBL] [Abstract][Full Text] [Related]
15. Expression, purification and biological characterization of human vasostatin120-180 in Pichia pastoris.
Lin Y; Yang X; Lu M; Zhuang H; Hua ZC
Protein Expr Purif; 2013 Dec; 92(2):141-7. PubMed ID: 24096091
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the purification of biologically active IL-7 cytokine expressed in Escherichia coli and Pichia pastoris.
Zaremba-Czogalla M; Stumpp C; Bonifacio E; Paul R
Protein Expr Purif; 2015 Jun; 110():65-71. PubMed ID: 25703052
[TBL] [Abstract][Full Text] [Related]
17. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
18. High-level expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Wang D; Shi L
Appl Biochem Biotechnol; 2009 Apr; 157(1):1-9. PubMed ID: 19306078
[TBL] [Abstract][Full Text] [Related]
19. Target cell-restricted apoptosis induction by 528scFv-TRAIL fusion protein specific for human EGFR and expressed in Escherichia coli.
Badran A; Asano R; Nakayama M; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kumagai I
Int J Oncol; 2010 May; 36(5):1229-34. PubMed ID: 20372797
[TBL] [Abstract][Full Text] [Related]
20. [Expression and antitumor activity of fusion protein RGD-TRAIL in Pichia pastoris].
Wang XF; Chen SZ
Yao Xue Xue Bao; 2015 May; 50(5):552-9. PubMed ID: 26234135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
